Byron Vaughn, MD

Assistant Professor of Medicine, Division of Gastroenterology, Hepatology and Nutrition

Byron Vaughn

Contact Info

Mailing Address:
420 Delaware Street, SE
MMC 36
Minneapolis, MN 55455

Administrative Assistant Name
Colleen Unger

Administrative Phone

Administrative Email

Administrative Fax Number

Assistant Professor of Medicine, Division of Gastroenterology, Hepatology and Nutrition


Medical School, Drexel University, Philadelphia, PA

Residency, Beth-Israel Deaconess Medical Center, Boston, MA

Fellowship, Beth-Israel Deaconess Medical Center, Boston, MA


Dr. Vaughn completed his Internal Medicine residency and Gastroenterology fellowship at Beth-Israel Deaconess Medical Center in Boston. There he developed both clinical and research interests in Inflammatory Bowel Disease. He worked with the IBD Center at BIDMC to study the effect of therapeutic manipulation of the microbiome in Crohn's disease as well as optimizing the management of anti-TNF medications. In addition to his research interests he has worked closely with the medical school teaching students and mentoring physicians in training in clinical and quality improvement research. His main clinical interests include Crohn's disease, Ulcerative Colitis as well as Microscopic colitis and Celiac disease. He also sees patients with recurrent C. difficile colitis. His active areas of research involve clinical trials for IBD.

Awards & Recognition

  • 2017 Teacher of the year, University of Minnesota Gastroenterology Fellowship
  • 2017 50 Most Influential Volunteers, Crohn’s & Colitis Foundation, Minnesota/Dakotas Chapter 
  • 2017 Top Doctors, Minnesota Monthly 
  • 2017 Top Doctors: Rising Stars, Mpls.St.Paul Magazine


Research Summary/Interests

Dr. Vaughn is actively involved in both clinical and translational research for patient with IBD. The intestinal microbiota has recently been identified as a critical component of many intestinal pathways including immune tolerance and inflammation. Dr. Vaughn is working in collaboration with Dr. Alexander Khoruts to continue to understand how the microbiota functions to induce inflammation or tolerance. Additionally Dr. Vaughn has been a strong proponent for therapeutic drug monitoring. This includes monitoring drug levels for patient on anti-TNFs such as infliximab and adalimumab. His research demonstrates that by close monitoring of these medication and titration to a therapeutic window, patients have more effective disease control and less chance of developing anti-drug antibodies. He continues to study the effect of therapeutic drug monitoring on antibody development. 


  • Weingarden AR, Vaughn BP. Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. Gut Microbes 2017 May 4;8(3):238-252. [Invited review] 
  • Min MX, Sklow B, Vaughn BP. Intussusception after Routine Colonoscopy: A Rare Complication. ACG Case Rep J. 2017 Apr 26;4:e63. 
  • Staley C, Vaughn BP, Graiziger CT, Singroy S, Hamilton MJ, Yao D, Chen C, Khoruts A, Sadowsky MJ. Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota. Gut Microbes. 2017 May 4;8(3):276-288. 
  • Staley C, Hamilton MJ, Vaughn BP, Graiziger CT, Newman KM, Kabage AJ, Sadowsky MJ, Khoruts A. Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study. Am J Gastroenterol. 2017 Jun;112(6):940-947. 
  • Newman KM, Rank KM, Vaughn BP, Khoruts A. Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. Gut Microbes. 2017 Jan 19:1-7. 
  • Staley C, Vaughn BP, Graiziger CT, Sadowsky MJ, Khoruts A. Gut-sparing treatment of urinary tract infection in patients at high risk of Clostridium difficile infection. J antimicrob Chemother. 2017 Feb;72(2):522-528. 
  • Vaughn BP, Vatanen T, Allegretti RJ, Bai A, Xavier RJ, Korzenik J, Gevers D, Ting A, Robson SC, Moss AC. Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn’s Disease. Inflamm Bowel Dis. 2016 Sep;22(9):2182-90. 
  • Campbell JP, Vaughn BP. Optimal delivery of follow-up care after surgery for Crohn’s disease: current perspectives. Clin Exp Gastroenterol. 2016 Aug 8;9:237-48.



Gastroenterology Clinic;University of Minnesota Medical Center

Board Certifications

  • Internal Medicine
  • Gastroenterology

Clinical Interests

Inflammatory Bowel Disease; Clinical trials in IBD; Crohn's Disease; Ulcerative Colitis; Microscopic colitis